A61K 49 - Preparations for testing in vivo

Patents for A61K 49 - Preparations for testing in vivo (35,376)
10/2002
10/31/2002	WO2001052898A9 Methods for incorporating metal chelators at carboxyl-terminal site of peptides
10/31/2002	WO2001052746A9 Versatile hydrophilic dyes
10/31/2002	WO2001049184A9 Radiofrequency apparatus and method for accessing a biopsy site
10/31/2002	WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002	US20020162124 Useful for studying phospholipid and cholesterol metabolism and for screening compounds designed to treat disorders of phospholipid and/or cholesterol metabolism
10/31/2002	US20020161298 Methods and chemical preparations for time-limited marking of biopsy sites
10/31/2002	US20020160969 Nucleosides and oligonucleotides containing boron clusters
10/31/2002	US20020160943 Tumor-activated prodrug compounds and treatment
10/31/2002	US20020160431 Insertion a guide; supplying washing fluid into breast duct; discharging; accumulation; cytolysis analyzing; cancer dialysis
10/31/2002	US20020160362 Measurement variations of allele polypeptides gene; diagnosis of arthritis, cancer
10/31/2002	US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image
10/31/2002	US20020159948 Introducing a chemical compound to a patient, the compound being a complex of a fluorescent marker and a radioactive marker, cells are then collected through noninvasive means, observation of fluorescence indicates cancer or precondition
10/31/2002	US20020157293 Tattoo method and system for medical and surgical applications
10/31/2002	DE10120428A1 Orales Mittel für die Human- und Veterinärmedizin Oral agent for human and veterinary medicine
10/31/2002	CA2444615A1 Production and use of a suspension composition comprising an ultrasound contrast medium
10/30/2002	EP1252885A2 Methods of preparing gas and gaseous precursor-filled microspheres
10/30/2002	EP1252884A2 Oral composition for human or veterinairy medicine
10/30/2002	EP1251877A1 Site specific binding system, nuclear imaging compositions and methods
10/30/2002	EP1251876A2 Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
10/30/2002	EP1251875A1 Use of contrast agents in the manufacture of diagnostic agent for the visualisation of the intestinal lumen
10/30/2002	EP1251840A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
10/30/2002	EP1251835A2 Closure of bacterial ghosts
10/30/2002	EP1251780A1 LUMINESCENT i IN VIVO /i GLUCOSE MEASUREMENT
10/30/2002	EP1061957B1 Manganese (ii) chelates with high relaxivity in serum
10/30/2002	EP0662972B1 3-,8-substituted deuteroporphyrine derivatives, pharmaceuticals containing them and methods of producing them
10/30/2002	CN1377284A Multi-stage method for producing gas-filled microcapsules
10/29/2002	WO2001085799A1 Fluorescein isothiocyanate (fitc) sinistrin, its production and use
10/29/2002	US6471942 Imaging and treatment method for body
10/29/2002	US6471700 Apparatus and method for accessing biopsy site
10/29/2002	US6471660 Non-invasively obtaining mammary fluid; determining a risk of a mammary gland disease such as cancer; quantifing the amount of a biological factor, especially a carotenoid, in the mammary fluid and comparing to a control
10/29/2002	CA2045552C Cancer related haptoglobin
10/28/2002	WO2001082977A1 Liposomes containing hydrophobic iodo compound
10/24/2002	WO2002083926A2 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083854A2 Antibodies to vla-1
10/24/2002	WO2002083381A2 Method and compositions for inhibiting cellulolytic symbionts
10/24/2002	WO2002083110A2 Animal model for evaluating analgesics
10/24/2002	WO2002083105A2 Composition for enhanced absorption of nsaids
10/24/2002	WO2002082972A2 Method and apparatus to optimize drug therapy
10/24/2002	WO2002011771A3 Contrast medium consisting of geometrically highly ordered proteins for medical diagnostics
10/24/2002	WO2001074406A3 Dendrimer composition for magnetic resonance analysis
10/24/2002	WO2001056612A9 Animal model for testing of immunotherapies
10/24/2002	US20020157118 Human neurofilament genes may be introduced into such genetically non-human animals to produce improved models of physiology of human neurofilament proteins which may be used to study human neurodegenerative disorders
10/24/2002	US20020156483 Vertebroplasty injection device and bone cement therefor
10/24/2002	US20020156117 Receptor-avid exogenous optical contrast and therapeutic agents
10/24/2002	US20020155600 Cell composition containing optic sensors for use in the detection of preferential particles in sample
10/24/2002	US20020155527 Nucleotide sequences coding membrane protein for use in the treatment of tumors
10/24/2002	US20020155520 Coating particle with dye; contacting cell; releasing dye
10/24/2002	US20020155509 Retentate chromatography and protein chip arrays with applications in biology
10/24/2002	US20020155470 Intercalation compound for use in the diagnosis and detection of genetic disorders
10/24/2002	US20020155102 Administering to a mammal formulation of cationic lipids and a substance that affects angiogenesis; allowing formulation to associate with angiogenic endothelial cells of an angiogenic blood vesselsuch that it enters cells
10/24/2002	US20020152756 Hyperpolarized noble gas extraction methods, masking methods, and associated transport containers
10/24/2002	CA2455274A1 Animal model for evaluating analgesics
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2443903A1 Antibodies to vla-1
10/24/2002	CA2443244A1 Enzymes
10/23/2002	EP1250333A1 Dendrimer precursor dyes for imaging
10/23/2002	EP1250158A2 Hyperpolarisation of a gas
10/23/2002	EP1250151A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
10/23/2002	EP1250149A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer
10/23/2002	EP1250095A1 Versatile hydrophilic dyes
10/23/2002	EP1250094A1 Tunable indocyanine dyes for biomedical applications
10/23/2002	EP1250093A1 Novel indocyanine dyes
10/23/2002	EP1250092A1 Novel dyes
10/23/2002	EP1250091A1 Hydrophilic cyanine dyes
10/23/2002	EP1003458B1 Liver function test
10/23/2002	EP0177545B2 Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents
10/23/2002	CN1376074A Antibody-dye conjugates for binding to target structures of angiogenesis in order to introperatively depict tumor peripheries
10/23/2002	CN1092989C Method for preparing microparticle for use as diagnosing imaging and composition comprising microparticle obtained y same method
10/23/2002	CN1092988C Thermally stabilized contrast agent
10/23/2002	CN1092987C Delivery of therapeutic agents to receptors using polysaccharides
10/22/2002	US6469208 Crystalline iohexol containing residual solvents (isopropyl alcohol) above 100 ppm is suspended in a combination of ethanol and water, heated, filtered and then dried
10/22/2002	US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
10/22/2002	US6469146 Radiopharmaceutical products suitable for the selective labeling of lymphocytes, and their preparation
10/22/2002	US6468802 Anlyzing expired 13c-labeled (isotopes) carbon monoxide following ingestion of labeled glucose source
10/22/2002	US6468506 Dissolving polyesters of hydroxycarboxylic acids in water miscible organic solvent, adding perfluorinated compound, forming aqueous dispersion, removing solvent and freeze drying
10/22/2002	US6468505 Technique to monitor drug delivery noninvasively in vivo
10/22/2002	US6468503 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
10/22/2002	US6468502 Paramagnetic macromolecules with higher proton relaxivity; lower dosage and increased signal intensity; detecting vascular diseases; differentiating tissue blood supply levels; distinguishing myocardial infarction from ischemia
10/22/2002	US6468219 Implantable telemetric transcranial doppler device
10/17/2002	WO2002082462A2 Stabilization and terminal sterilization of phospholipid formulations
10/17/2002	WO2002082041A2 Production and use of novel peptide-based agents for use with bi-specific antibodies
10/17/2002	WO2002081653A2 An animal model for enteric pathogens
10/17/2002	WO2002081649A2 ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
10/17/2002	WO2002081636A2 Protein modification and maintenance molecules
10/17/2002	WO2002081634A2 Imaging nucleic acid delivery
10/17/2002	WO2002081430A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	WO2002080985A1 Increasing retrievable fluid from a breast duct
10/17/2002	WO2002080960A2 Treatment of neuropathologies associated with expression of tnf-alpha
10/17/2002	WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	WO2002080778A1 Method for viewing tumor tissue located within a body cavity
10/17/2002	WO2002080774A2 Method for improved measurement of local physical parameters in afluid-filled cavity
10/17/2002	WO2002080757A2 Novel functional agents for magnetic resonance imaging
10/17/2002	WO2002080756A2 Imaging systems for in vivo protocols
10/17/2002	WO2002080754A2 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002032860A3 Dynamic organ function monitoring agents
10/17/2002	WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2002006287A3 Macrocyclic mri contrast agents

1 ... 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 ... 354